<aside>
This page explains how much additional funding GOAL 3 can use well, what different amounts would pay for, and what sets the pace of scale-up.
</aside>
Additional funding only creates impact if GOAL 3 can turn it into well-implemented wards that stay in use. Additional funding can pay for new implementations, subsidised access for hospitals that cannot cover the full cost, entry into new countries, evidence generation, and the capacity to deliver at scale. Each runs into different bottlenecks, which this page sets out.
We look at absorption capacity in two ways:
<aside>
</aside>
Operational absorption capacity is GOAL 3’s ability to translate additional funding into high-quality IMPALA implementations while maintaining adoption, uptime, and long-term sustainability. It is therefore not simply determined by how many IMPALA monitors can be manufactured or purchased. The main constraint is the capacity to implement the platform well across facilities and provide the support required for sustained use.
GOAL 3's delivery capacity depends on three factors that multiply each other:
Operational scale = (1) GOAL 3 implementation capacity × (2) scalability of the intervention × (3) implementation partner capacity
Importantly, these factors are multipliers rather than independent capacity pools. Adding more service coordinators increases capacity directly, while stronger implementation partners and more scalable implementation tools increase the number of facilities that each coordinator can support.
<aside>
</aside>
Operational capacity sets how much GOAL 3 can implement. Health-system capacity is about where that funding should go. Not every implementation has the same value: it depends on unmet need, existing coverage, the strength of local partners and government pathways, and how much evidence a country still needs before it adopts IMPALA more widely. The same amount of funding does different work depending on how established GOAL 3 already is in a market, and the constraint it runs into is different at each stage.
Some funding produces no implementations in any country. Evidence generation, policy work and partner development create the conditions for later implementations and for local financing. GOAL 3 does not put all funding where the immediate impact per dollar is highest, because a portfolio limited to near-term implementations in established countries would eventually stop growing.
<aside>
</aside>
Which constraint limits absorption depends on the size of the commitment.
For funders, this means multi-year commitments with forward visibility go furthest: they let GOAL 3 plan hiring, production and partner development ahead of volume. GOAL 3 would rather agree a realistic schedule with a funder than commit to a volume it cannot implement well.
<aside>
</aside>
The table shows what different amounts of additional funding would pay for, how quickly, and what limits the pace. All figures are planning estimates, not commitments. Below about US$500,000, funding turns almost entirely into ward implementations, and implementation capacity sets the pace. Larger amounts also need to cover country entry, partner development, evidence and the capacity to deliver, or the implementations become harder to sustain.
| Funding amount | Timeframe | What it unlocks | Modelled deaths averted a year, once live: central (observed) | Main constraint | Confidence |
|---|---|---|---|---|---|
| ~US$30,500 (with minimum 10% hospital share) | 3–6 months | One paediatric ward through the Scaling IMPALA Fund: 10 IMPALA Monitors, server hub, installation, training and three years of IMPALA Care. About 3,000 admissions a year; ~42 health workers trained. | ~14 (48–57) | None at this scale; delivered within existing country capacity | High |
| ~US$90,000 | 3–6 months | Three wards in a country where GOAL 3 already operates. About 9,000 admissions a year; ~126 health workers trained. | ~40 (144–171) | Hardware lead time of two to six months from order to installed site | High |
| ~US$245,000 | 6–12 months | Eight wards across two or three established countries, or six wards with a monitoring and evaluation component. About 24,000 admissions a year; ~336 health workers trained. | ~110 (384–456) | Service Coordinator capacity in the receiving countries | High |
| ~US$300,000 | 18–24 months | Independent evaluation of the installed base across about 60 hospitals in Malawi, Rwanda and Tanzania (core design). Protocol published by Q2 2027, first results by end 2028. About US$0.5–0.6m with some 30 comparison sites. | – | [to confirm] | High |
| ~US$300,000 | 6–12 months | Integration of Smart Triage and Smart Discharge (University of British Columbia) into IMPALA, plus a pilot. | – | [to confirm] | High |
| US$250,000–350,000 per country | 9–18 months | Entry into a new country, such as Ethiopia or Nigeria: market assessment, regulatory registration, government engagement and partner selection. | – | Regulatory approval and partner validation, at six to twelve months per partner | Medium |
| ~US$490,000 | 9–18 months | Sixteen wards, or a multi-ward programme in one country combined with partner development and MEL support. About 48,000 admissions a year; ~672 health workers trained. | ~220 (768–912) | Local cost-sharing, and Service Coordinator recruitment at two to three months per hire | Medium |
| US$0.5–1m | 12–24 months | Hospital-wide expansion in one major referral hospital (200–400 monitors), which can be split into tranches of wards or departments (see ‣ section 4). | Not yet modelled (mixed ward types) | Hospital and Ministry of Health readiness, procurement timelines | Medium |
| ~US$1.5m | 24 months | Scale-up in Kenya and/or Tanzania with ECSA-HC: about 30 hospitals, wards included, with 30% co-financing, so that governments build IMPALA into their own budgets. | Not yet modelled | Government co-financing and budget commitments | Medium |
| US$2.55–3.6m | Hospital by hospital as funding becomes available | First phase of Rwanda's national IMPALA Scale-Up Plan: neonatal and paediatric wards in all 52 public hospitals, about 1,300 monitors. | Not yet modelled | Government readiness and procurement cycles | Medium |
| ~US$5.3m | 2027–2028 | The full Scaling IMPALA Fund plan: about 156 paediatric wards (about 468,000 admissions a year), the independent evaluation, and the Foundation's own team. | ~2,100 (7,500–8,900) | Production and hiring planned against volume; works best as a multi-year commitment | Medium |
| US$5–7m | 36–48 months | A stand-alone randomised controlled trial (earlier estimate). A randomised design inside the Beginnings Fund rollout is being explored, with a decision by end 2027. | – | Trial design and partner capacity | Lower |
| Beyond | - | Multi-country programmes through ECSA-HC, and paediatric wards in hospitals where the Beginnings Fund equips the neonatal unit (see ‣ section 4.3). No fixed ceiling. | – | – | Medium |
Ward figures assume 3,000 paediatric admissions per ward a year and 3.8% baseline mortality. The central estimate applies Rethink Priorities' discounted 12% mortality reduction; the figure in brackets applies the 1.6–1.9 percentage point reductions observed in two Malawian hospitals. Deaths averted are modelled, not counted. Every amount can be reduced by cost-sharing: hospitals funded through the Scaling IMPALA Fund contribute at least 10% of total five-year costs, and 20% on average. Confidence refers to whether GOAL 3 could deploy the funding at this scale within the stated timeframe, not to the impact estimates.